China Human Vaccine Industry Report, 2016-2020

Description: Amid the unsafe domestic vaccine events, China's human vaccine lot release volume in 2015 fell by 17.9% year on year to only 650 million doses, touching a 5-year low. Moreover, with the improvements in domestic vaccine supply capacity and vaccine circulation safety, China's human vaccine import volume has showed a year-by-year decline in recent years, with the imports for 2015 totaling 173.9 tons, down 17.5% year on year.

Affected by China's less-developed economy, existing national vaccine prevention policies and people's awareness of epidemic prevention, free EPI vaccines prevail in China. But the market share is falling, with the free EPI vaccine lot release volume in 2015 accounting for about 74.3% of the total.

The Chinese free human vaccine market is still dominated by the subsidiaries of China National Biotec Group - including Beijing Tiantan Biological Products, Chengdu Institute of Biological Products Co., Ltd., Shanghai Institute of Biological Products Co., Ltd., Lanzhou Institute of Biological Products Co., Ltd., Wuhan Institute of Biological Products Co., Ltd., and Changchun Institute of Biological Products Co., Ltd. -and state-owned enterprises like Institute of Medical Biology under Chinese Academy of Medical Sciences. In 2015, the EPI vaccine lot release volume of Chinese state-owned enterprises made up 72.6% of the total.

However, as China gradually relaxes controls on the vaccine market, private companies have unexpectedly emerged in extra EPI vaccine market segment in recent years, with the proportion increasing constantly. In 2015, their lot release volume accounted for 70% in this market segment. Furthermore, these enterprises hold a dominant position in haemophilus influenza B (Hib), human rabies vaccine, varicella vaccine, influenza vaccine, and other market segments.

Being upbeat about China's human vaccine demand market and exports, many vaccine producers are stepping up vaccine R&D or expanding capacity.

So far, there are four enterprises in China, namely Walvax Biotechnology, Beijing Minhai Biotechnology, SINOVAC BIOTECH, and Lanzhou Institute of Biological Products, whose 13-valent pneumococcal conjugate vaccine (PCV13) have entered clinical research stage; recombinant HPV vaccines, developed by Shanghai Zerun Biotechnology, a subsidiary of Walvax Biotechnology, and Xiamen Innovax Biotech, have entered phase III clinical research phase.

In 2015, CFDA approved the production and registration application of the world's first inactivated Sabin strain polio vaccine, which was developed by the Institute of Medical Biology of the Academy of Medical Sciences. The vaccine was brought to market on June 30, 2015.

Over the same year, the inactivated enterovirus 71 (EV71) vaccines (for hand-foot-mouth disease prevention), also developed by the Institute of Medical Biology of the Academy of Medical Sciences was made available after the approval from CFDA; SINOVAC BIOTECH and Wuhan Institute of Biological Products, are applying for drug production license of inactivated enterovirus 71 (EV71) vaccines; Hualan Bio and Beijing ZhifeiLzhu Biopharmaceutical (a subsidiary of Chongqing Zhifei Biological Products) have submitted the application of clinic trial of inactivated enterovirus 71 (EV71) vaccines.

China Human Vaccine Industry Report, 2016-2020 highlights the following:
- Operating environment, overall situation, sales channel, etc. of China human vaccine industry;
- Supply & demand, competitive landscape, import & export, and development forecast of the Chinese human vaccine market;
- Supply & demand, competitive landscape, and market prices of 10 vaccine product segments in China, including hepatitis B vaccine, influenza vaccine, rabies vaccine, and pneumococcal vaccine;
- Operation, vaccine business, and development prospects of 16 Chinese human vaccine companies.

Contents:
1. Overview of Vaccine Industry
   1.1 Definition & Classification
   1.2 Industry Chain
2. China Human Vaccine Industry & Market
   2.1 Overview
   2.2 Operating Environment
      2.2.1 International Market
      2.2.2 Policy Environment
      2.2.3 Biopharmaceutical Market in China
   2.3 Status Quo
   2.4 Supply & Demand
   2.5 Competition Pattern
   2.6 Dynamics
   2.7 Sales Channel

3. Human Vaccine Market Segments in China
   3.1 Hepatitis B Vaccine
      3.1.1 Supply & Demand
      3.1.2 Competition Pattern
      3.1.3 Market Price
   3.2 Meningococcal Vaccines
      3.2.1 Supply & Demand
      3.2.2 Competition Pattern
      3.2.3 Market Price
      3.2.4 Market Forecast
   3.3 Hepatitis A Vaccine
      3.3.1 Supply & Demand
      3.3.2 Competition Pattern
      3.3.3 Market Price
      3.3.4 Market Forecast
   3.4 Influenza Vaccine
      3.4.1 Supply & Demand
      3.4.2 Competition Pattern
      3.4.3 Market Price
   3.5 Hib Vaccine
      3.5.1 Supply & Demand
      3.5.2 Competition Pattern
      3.5.3 Market Price
      3.5.4 Market Forecast
   3.6 Rabies Vaccine
      3.6.1 Supply & Demand
      3.6.2 Competition Pattern
      3.6.3 Market Price
      3.6.4 Market Forecast
   3.7 Varicella Vaccine
      3.7.1 Supply & Demand
      3.7.2 Competition Pattern
      3.7.3 Market Price
   3.8 Pneumococcal Vaccines
      3.8.1 Supply & Demand
      3.8.2 Competition Pattern
      3.8.3 Market Price
   3.9 DTP Vaccine
      3.9.1 Supply & Demand
      3.9.2 Competition Pattern
      3.9.3 Market Dynamics & Forecast
   3.10 Poliomyelitis Vaccine
      3.10.1 Supply & Demand
      3.10.2 Competition Pattern

4. China’s Import and Export of Vaccines
   4.1 Export
      4.1.1 Export Volume and Value
      4.1.2 Export Country and Region
   4.2 Import
4.2.1 Import Volume and Value
4.2.2 Import Country and Region

5. Major Vaccine Manufacturers in China
5.1 China National Biotec Group
5.1.1 Beijing Tiantan Biological Products Co., Ltd
5.1.2 Chengdu Institute of Biological Products Co., Ltd.
5.1.3 Shanghai Institute of Biological Products Co., Ltd.
5.1.4 Wuhan Institute of Biological Products Co., Ltd.
5.1.5 Lanzhou Institute of Biological Products Co., Ltd.
5.1.6 Changchun Institute of Biological Products Co., Ltd.
5.2 Hualan Biological Engineering Inc.
5.2.1 Profile
5.2.2 Operation
5.2.3 Revenue Structure
5.2.4 Gross Margin
5.2.5 Clients and Suppliers
5.2.6 R&D Cost and Investment
5.2.7 Vaccine Business
5.2.8 Development and Prospects
5.3 Chongqing Zhifei Biological Products Co., Ltd.
5.3.1 Profile
5.3.2 Operation
5.3.3 Revenue Structure
5.3.4 Gross Margin
5.3.5 Clients
5.3.6 R&D Cost and Investment
5.3.7 Development and Prospects
5.4 Walvax Biotechnology Co, Ltd.
5.4.1 Profile
5.4.2 Operation
5.4.3 Revenue Structure
5.4.4 Gross Margin
5.4.5 Clients and Suppliers
5.4.6 R&D Cost and Investment
5.4.7 Development and Prospects
5.5 Sinovac Biotech Ltd.
5.5.1 Profile
5.5.2 Operation
5.5.3 Revenue Structure
5.5.4 R&D Cost and Investment
5.5.5 Development and Prospects
5.6 Liaoning Cheng Da Co., Ltd.
5.6.1 Profile
5.6.2 Operation
5.6.3 Revenue Structure
5.6.4 Gross Margin
5.6.5 Clients
5.6.6 Liaoning Chengda Biotechnology Co., Ltd.
5.6.7 Development and Prospects
5.7 Changchun BCHT Biotechnology Co. Ltd.
5.7.1 Profile
5.7.2 Operation
5.8 Changchun Changsheng Life Sciences Limited
5.8.1 Profile
5.8.2 Operation
5.9 Zhejiang Tianyuan Bio-Pharmaceutical Co., Ltd.
5.9.1 Profile
5.9.2 Operation
5.10 Shenzhen Kangtai Biological Products Co. Ltd.
5.10.1 Profile
5.10.2 Operation
5.11 Dalian Hissen Bio-Pharm Co., Ltd.
List of Charts

- Classification of Vaccines
- Vaccine Industry Chain
- EPI Human Vaccine Varieties in China, 2015
- Global Human Vaccine Market Scale, 2008-2015
- Sales Value of the Global Top 5 Human Vaccine Manufacturers, 2008-2015
- Policies in Vaccine Industry
- Revenue and Total Profit of Bio-pharmaceutical Industry in China, 2007-2014
- China's Human Vaccine Market Scale, 2007-2015
- Major Human Vaccine Varieties and Producers in China
- Gross Margin of Major Human Vaccine Manufacturers in China, 2007-2015
- The Release and Percentage (by Volume) of EPI and Extra EPI Vaccines in China, 2007-2015
- China's EPI Human Vaccine Market Shares by Release, 2008-2015 (by Enterprise Property)
- China's Extra EPI Human Vaccine Market Shares by Release, 2008-2015 (by Enterprise Property)
- Vaccine Revenue of Major Vaccine Enterprises in China, 2011-2015
- Some Events Related to Vaccine Business of Foreign Enterprises in China, 2011-2015
- Vaccine Distribution Channel in China
- Market Prices of Hepatitis B Vaccine in Some Regions of China, 2014
- Meningitis Morbidity and Mortality in China, 2008-2014
- Meningococcal Vaccines Lot Release Volume in China by Type, 2007-2015
- Market Prices of Meningococcal Vaccines in Some Regions of China, 2015
- Hepatitis A Morbidity and Mortality in China, 2008-2013
- Market Price of Hepatitis A Vaccine in China, 2015
- Consumption Forecast of Hepatitis A Vaccine in China, 2015-2020
- Influenza Morbidity and Mortality in China, 2008-2013
- H1N1 Influenza Morbidity and Mortality in China, 2009-2012
- China's Influenza Vaccine Lot Release Volume (by Type), 2007-2015
- Influenza Subunit Vaccine Suppliers and Lot Release Volume in China, 2007-2012
- Market Price of Influenza Vaccine in China, 2015
- Market Prices of Hib Vaccine in Some Regions of China, 2015
- Sales Volume of Hib Vaccine in China, 2015-2020 (mln dosages)
- Rabies Morbidity and Mortality in China, 2007-2014
- Demand Forecast of Human Rabies Vaccine in China, 2015-2020 (mln person-portions)
- Market Prices of Pneumococcal Vaccines in Some Regions of China, 2015
- Export Volume and Value of Human Vaccine in China, 2009-2015
- Export Average Unit Price of Human Vaccine in China, 2009-2015
- China's Human Vaccine Export Volume and Value by Country, 2015
- Import Volume and Value of Human Vaccine in China, 2009-2015
- Import Average Unit Price of Human Vaccine in China, 2009-2015
- China's Human Vaccine Import Volume and Value by Country, 2015
- Major Shareholding Companies of Tiantan Biological and Their Revenue, Net Income, 2015
- Revenue and Operating Income of Beijing Tiantan Biological Products, 2009-2016
- Revenue Breakdown of Beijing Tiantan Biological Products by Sector, 2008-2015
- Revenue Breakdown of Beijing Tiantan Biological Products by Region, 2007-2015
- Beijing Tiantan Biological Products' Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2015
- Beijing Tiantan Biological Products' Revenue from Top 5 Customers and % of Total Revenue, 2008-2015
- Gross Margin of Beijing Tiantan Biological Products by Sector, 2008-2015
- R&D Costs and % of Total Revenue of Beijing Tiantan Biological Products, 2009-2015
- Main R&D Products and Progress of Beijing Tiantan Biological Products as of the end of 2015
- Vaccine Revenue of Beijing Tiantan Biological Products, 2008-2015
- Revenue and Operating Income of Beijing Tiantan Biological Products, 2015-2020E
- Vaccine Varieties of Chengdu Institute of Biological Products
- Vaccine Lot Release Volume Breakdown of Chengdu Institute of Biological Products by Product, 2009-2015
- Vaccine Varieties of Shanghai Institute of Biological Products
- Vaccine Lot Release Volume Breakdown of Shanghai Institute of Biological Products by Product, 2009-2015
- Vaccine Lot Release Volume Breakdown of Wuhan Institute of Biological Products by Product, 2009-2015
- Vaccine Lot Release Volume Breakdown of Lanzhou Institute of Biological Products by Product, 2009-2015
- Vaccine Lot Release Volume Breakdown of Changchun Institute of Biological Products by Product, 2009-2015
- Revenue and Operating Income of Hualan Biological Engineering, 2007-2016
- Revenue Breakdown of Hualan Biological Engineering by Sector, 2008-2015
- Gross Margin of Hualan Biological Engineering by Product, 2007-2014
- Hualan Biological Engineering's Revenue from Top 5 Customers and % of Total Revenue, 2008-2015
- Hualan Biological Engineering's Procurement from Top 5 Suppliers and % of Total Procurement, 2008-2015
- Name List, Procurement Amount of Top 5 Suppliers and % of Total Procurement, 2015
- R&D Costs and % of Total Revenue of Hualan Biological Engineering, 2008-2015
- Vaccine Revenue and Gross Margin of Hualan Biological Engineering, 2008-2015
- Revenue and Operating Income of Hualan Biological Engineering, 2015-2020E
- Revenue and Operating Income of Chongqing Zhifei Biological Products, 2008-2016
- Revenue Breakdown of Chongqing Zhifei Biological Products by Product, 2011-2015
- Revenue Breakdown of Chongqing Zhifei Biological Products by Region, 2009-2015
- Gross Margin of Chongqing Zhifei Biological Products, 2009-2015
- Gross Margins of Chongqing Zhifei Biological Products' Agent Vaccines, 2008-2015
- Chongqing Zhifei Biological Products' Revenue from Top 5 Customers and % of Total Revenue, 2008-2015
- Procurement Amount and % of Total Procurement of Chongqing Zhifei Biological Products' Top 5 Suppliers, 2012-2015
- R&D Costs and % of Total Revenue of Chongqing Zhifei Biological Products, 2008-2015
- Progress of Some Products under Research of Chongqing Zhifei Biological Products by the end of 2015
- Revenue and Operating Income of Chongqing Zhifei Biological Products, 2015-2020E
- Industrial Layout of Walvax Biotechnology
- Revenue and Operating Income of Walvax Biotechnology, 2009-2015
- Vaccines on the Market and Capacities of Walvax Biotechnology
- Revenue Breakdown of Walvax Biotechnology by Product, 2009-2015
- Revenue Breakdown of Walvax Biotechnology by Region, 2010-2015
- Gross Margin of Walvax Biotechnology by Product, 2007-2015
- Walvax Biotechnology's Revenue from Top5 Customers and % of Total Revenue, 2008-2015
- Walvax Biotechnology's Procurement from Top5 Suppliers and % of Total Procurement, 2008-2015
- Progress of Projects under Construction of Walvax Biotechnology by the end of 2015
- R&D Costs and % of Total Revenue of Walvax Biotechnology, 2009-2015
- Progress of the Products under Research of Walvax Biotechnology by the end of 2015
- Revenue and Operating Income of Walvax Biotechnology, 2015-2020E
- Revenue and Profit of Sinovac Biotech, 2007-2016
- Revenue Breakdown of Sinovac Biotech by Product, 2008-2015 (Unit: USD mln)
- R&D Costs and % of Total Revenue of Sinovac Biotech, 2008-2015
- Revenue and Operating of Sinovac Biotech, 2015-2020E
- Revenue and Operating Income of Liaoning Chengda, 2008-2015
- Revenue Breakdown of Liaoning Chengda by Sector, 2008-2015
- Gross Margin of Liaoning Chengda by Sector, 2008-2015
- Liaoning Chengda's Revenue from Top5 Customers and % of Total Revenue, 2008-2015
- Revenue and Net Income of Liaoning Chengda Biotechnology, 2012-2015
- Revenue Structure of Liaoning Chengda Biotechnology by Product, 2012-2015
- Name List and Revenue Contribution of Liaoning Chengda Biotechnology's Top5 Customers, 2013-2015
- Name List and Procurement Share of Liaoning Chengda Biotechnology's Top5 Suppliers, 2013-2015
- Revenue and Operating Income of Liaoning Chengda, 2015-2020E
- Vaccine Lot Release Volume and Percentage of Changchun BCHT, 2009-2015
- Revenue and Operating Income of Zhejiang Tianyuan Bio-Pharmaceutical, 2013-2014
- Vaccine Lot Release Volume and Percentage of Kangtai Biological, 2007-2015
- Revenue and Operating Income of Dalian Aleph Biomedical, 2013-2014
- Assets and Liabilities of Dalian Aleph Biomedical, 2013-2014
- Revenue and Operating Income of Beijing Minhai Biotechnology, 2013-2014
- Assets and Liabilities of Beijing Minhai Biotechnology, 2013-2014
- Vaccine Lot Release Volume Breakdown of Shenzhen Sanofi Pasteur Biological Products by Product, 2009-2015
- Revenue and Operating Income of Shenzhen Sanofi Pasteur Biological Products, 2013-2014
- Assets and Liabilities of Shenzhen Sanofi Pasteur Biological Products, 2013-2014


Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

**Order Information**
Please verify that the product information is correct and select the format(s) you require.

- **Product Name:** China Human Vaccine Industry Report, 2016-2020
- **Web Address:** [http://www.researchandmarkets.com/reports/3771357/](http://www.researchandmarkets.com/reports/3771357/)
- **Office Code:** SCPLJFFV

**Product Formats**
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User:</td>
<td>USD 2500</td>
</tr>
<tr>
<td>Hard Copy:</td>
<td>USD 2700 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide:</td>
<td>USD 3900</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

**Contact Information**
Please enter all the information below in **BLOCK CAPITALS**

<table>
<thead>
<tr>
<th></th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First Name:</td>
<td></td>
<td>Last Name:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td></td>
<td>Job Title:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td></td>
<td>Address:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td></td>
<td>Postal / Zip Code:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td></td>
<td>Phone Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World